ProterixBio, which specializes in products that aid in the development of new treatments for pulmonary conditions, including chronic obstructive pulmonary disease (COPD), announced the appointment of Fernando Martinez, MD, to its Scientific and Medical Advisory Board.
“ProterixBio is thrilled to have Dr. Martinez join” the board, Grace E. Colón, PhD, ProterixBio’s president and chief executive officer, said in a press release. “His decades of leadership in the field and passion for our vision and mission will help us at a critical time as we soon reach feasibility stage for our first product for COPD disease management.”
Dr. Martinez, the executive vice chair of medicine at Weill Cornell Medical College, is a translational researcher in chronic lung disease. He will help ProterixBio through strategic advice regarding clinical research studies, as well as with the development of products to improve pulmonary care.
“I am honored and excited to advise ProterixBio on critical diseases such as COPD and idiopathic pulmonary fibrosis,” he said. “I look forward to collaborating with the company on clinical studies designed to better assess their disease. A better evaluation of patients via molecular and traditional methods will ultimately benefit pulmonary patients through better management of their disease, fostering personalized care and, hopefully, improving outcomes and relieving burden on our patients.”
Dr. Martinez received both his bachelor’s and doctor of medicine degree at the University of Florida, and completed his internal medicine residency at Beth Israel Hospital/Harvard Medical School in 1986. He served as an assistant professor and, later, as a professor of medicine at the University Michigan, until moving to Weill Cornell in 2014, and he has been included on the list of “Best Doctors of America” every year since 2002.
He has authored 326 peer-reviewed scientific articles, 36 reviews, and 32 book chapters.